-
Maxim Group Downgrades Co-Diagnostics (CODX) to Hold
-
Co-Diagnostics receives Australian patent for PCR platform technology
-
Maxim Group Starts Co-Diagnostics (CODX) at Buy
-
Co-Diagnostics (CODX) Reports In-Line Q3 EPS
-
Co-Diagnostics forms joint venture in Saudi Arabia for PCR platform
-
Co-Diagnostics develops sample prep instrument for tuberculosis testing
-
Co-Diagnostics signs MOU for Saudi Arabia joint venture
-
H.C. Wainwright Reiterates Neutral Rating on Co-Diagnostics (CODX)
-
Co-Diagnostics (CODX) Tops Q2 EPS by 43c
-
Co-Diagnostics (CODX) Tops Q1 EPS by 10c
-
Co-Diagnostics (CODX) PT Lowered to $1 at H.C. Wainwright
-
Co-Diagnostics (CODX) Wins Dismissal of Class Action Lawsuit
-
Co-Diagnostics (CODX) to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance
-
Co-Diagnostics (CODX) Tops Q3 EPS by 1c
-
Co-Diagnostics (CODX) Completes Updated Clade Ib Analysis of 2-Gene Mpox RUO Test
-
Co-Diagnostics (CODX) PT Lowered to $1.50 at H.C. Wainwright
-
Co-Diagnostics (CODX) Tops Q2 EPS by 9c
-
Co-Diagnostics (CODX) Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

